Abstract
In Australia it is estimated that within the next 10 years, health care costs related to the management of urinary incontinence will be in the order of 1.2 billion dollars annually. The prevalence of urinary incontinence in Australia is estimated at between 34% and 45% in women and between 4% and 15% in men depending on the criteria used and subpopulations studied.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Canada: Sender Herschorn
Canadian Institute for Health Information (2010) National Health Expenditure Trends, 1975 to 2010. CIHI, Ottawa, ON
Corcos J, Schick E (2004) Prevalence of overactive bladder and incontinence in Canada. Can J Urol 11:2278–2284
Herschorn S, Gajewski J, Schulz J, Corcos J (2008) A population-based study of urinary symptoms and incontinence: the Canadian urinary bladder survey. BJU Int 101:52–58
Milsom I, Irwin DE (2007) A cross-sectional, population-based multinational study of the prevalence of overactive badder and lower urinary tract symptoms: results from the EPIC study. Eur Urol Suppl 6:4–9
Italy: Antonella Giannantoni
Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006a) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49:704–709
Giannantoni A, Di Stasi SM, Nardicchi V, Zucchi A, Macchioni L, Bini V, Goracci G, Porena M (2006b) Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J Urol 175:2341–2344
Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 62:259–264
Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697
Japan: Yukio Homma
Anger JT, Weinberg A, Suttorp MJ et al (2010) Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 183:2258–2264
Homma Y, Yoshida M, Seki N et al (2006) Symptom assessment tool for overactive bladder syndrome – overactive bladder symptom score. Urology 68:318–323
Homma Y, Ueda T, Tomoe H et al (2009) Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol 16:597–615
Miyagawa I, Watanabe T, Isoyama T, Honda M et al (2010) Experience with injections of botulinum toxin type A into the detrusor muscle. Aktuelle Urol 41:S24–S26
Korea: Kyu-Sung Lee
Chung KJ et al (2005) The efficacy of botulinum toxin injection to the external urethral sphincter for detrusor external sphincter dyssynergia Korean. J Urol 46:604–609
Park DS et al (2006) Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 47:706–714
Singapore: Michael Wong
Lie KY, Wong MY, Ng LG (2010) Botulinum toxin A for idiopathic detrusor overactivity. Ann Acad Med Singapore 39:714–715
Lim SK, Quek PL (2008) Intraprostatic and bladder-neck injection of Botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study. Eur Urol 53:620–625
Tow AM, Toh KL, Pang SP, Consigliere D (2007) Botulinum toxin type A for refractory detrusor overactivity in spinal cord injured patients in Singapore. Ann Acad Med Singapore 36:11–17
United Kingdom Urogynaecology: Anga S. Arunkalaivanan
Abbott JA, Jarvis SK, Lyons SD, Thomson A, Vancaille TG (2006) Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol 108:915–923
Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55:100–119
National Institute of Clinical Excellence (2006). http://www.nice.org.uk/
Sahai A, Dowson C, Khan MS, Dasguta P, GKTBS Group (2007) Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 75:552–558
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Chancellor, M.B., Smith, C.P. (2011). Perspectives from Around the World: Panorama of Where We Are and Where We Are Going. In: Botulinum Toxin in Urology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-03580-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-03580-7_11
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-03579-1
Online ISBN: 978-3-642-03580-7
eBook Packages: MedicineMedicine (R0)